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Keiji Umetani8, Darren J Kelly4 and Mikiyasu Shirai5Abstract
Objectives: Activation of RhoA/Rho-kinase (ROCK) is increasingly implicated in acute vasospasm and chronic
vasoconstriction in major organ systems. Therefore we aimed to ascertain whether an increase in ROCK activity
plays a role in the deterioration of coronary vascular function in early stage diabetes.
Methods: Synchrotron radiation microangiography was used to determine in vivo coronary responses in diabetic
(3 weeks post streptozotocin 65 mg/kg ip) and vehicle treated male Sprague–Dawley rats (n = 8 and 6). Changes in
vessel number and calibre during vasodilator stimulation before and after blockade of nitric oxide synthase and
cyclooxygenase were compared between rats. Acute responses to ROCK inhibitor, fasudil (10 mg/kg iv) was
evaluated. Further, perivascular and myocardial fibrosis, arterial intimal thickening were assessed by histology, and
capillary density, nitrotyrosine and ROCK1/2 expressions were evaluated by immunohistochemical staining.
Results: Diabetic rats had significantly elevated plasma glucose (P < 0.001 vs control), but did not differ in fibrotic
scores, media to lumen ratio, capillary density or baseline visible vessel number or calibre. Responses to acetylcholine
and sodium nitroprusside stimulation were similar between groups. However, in comparison to control rats the diabetic
rats showed more segmental constrictions during blockade, which were not completely alleviated by acetylcholine, but
were alleviated by fasudil. Further, second order vessel branches in diabetic rats were significantly more dilated relative
to baseline (37% vs 12% increase, P < 0.05) after fasudil treatment compared to control rats, while visible vessel number
increased in both groups. ROCK2 expression was borderline greater in diabetic rat hearts (P < 0.053).
Conclusions: We found that ahead of the reported decline in coronary endothelial vasodilator function in diabetic rats
there was moderate elevation in ROCK expression, more widespread segmental constriction when nitric oxide and
prostacyclin production were inhibited and notably, increased calibre in second and third order small arteries-arterioles
following ROCK inhibition. Based on nitrotyrosine staining oxidative stress was not significantly elevated in early diabetic
rats. We conclude that tonic ROCK mediated vasoconstriction contributes to coronary vasomotor tone in early diabetes.Introduction
Diabetes is associated with coronary microvascular dys-
function due to an inability of the endothelium to maintain
vasodilatory tone both at rest [1] and during stress [2,3].
This previous work has primarily focused on later time-
points of diabetes, where microvascular damage is already* Correspondence: james.pearson@monash.edu
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reproduction in any medium, provided the orwell developed and thus difficult to reverse. As diabetes
progresses these individuals are subjected to a vastly in-
creased risk of ischaemic heart disease, acute myocardial
infarction, and stroke [4,5]. Utilising synchrotron radiation
(SR) microangiography, we have now demonstrated that
even in the early stages of diabetes in the coronary circula-
tion focal and segmental constrictions occur when prosta-
cyclin and nitric oxide contribution is prevented, although
globally basal endothelium-dependent vasodilation is main-
tained [6]. This impairment in vasodilatory capacity mayl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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myocardial infarction observed in advanced diabetes. Thus,
it is of paramount importance that the mechanisms under-
lying this localised dysfunction are further elucidated, at a
time point where potential intervention remains possible.
One pathway that is increasingly recognised to be in-
volved in the pathogenesis of cardiovascular disease is the
RhoA/ROCK pathway, which has been implicated in the
progression of conditions including hypertension [7], stroke
[8], coronary vasospasm and angina [9,10], ischemia-
reperfusion injury and heart failure [11,12]. RhoA is a
small plasma membrane bound guanosine-5'-triphosphate-
binding protein, which when stimulated, activates ROCK
[12]. It is thought that upregulation of RhoA/ROCK in the
diabetic vasculature [13] causes subsequent phosphoryl-
ation of downstream signalling targets including myosin
light chain phosphatase, and increased constriction of vas-
cular smooth muscle [14-16]. Thus there may be a role for
ROCK in the early diabetic coronary dysfunction we have
previously described [6].
Acute treatment with ROCK inhibitors has shown
promising results, with reduction in ischaemic damage
[15,17-19], improvement in cerebral vasodilation in type
II diabetic mice [20] and decreased vascular resistance
and increased peripheral blood flow in patients with
heart failure [11]. Notably, ROCK inhibitors may also have
beneficial outcomes in preventing the development of cor-
onary dysfunction, most likely by promoting or maintaining
increased expression and activity of vasoprotective endo-
thelial nitric oxide synthase (NOS) [14,21]. This study
therefore aimed to ascertain whether ROCK plays a role in
the deterioration of coronary vascular function in early
stage diabetes.
Methods
Animals and experiments at the synchrotron
Experiments were conducted at SPring-8, Japan Synchro-
tron Radiation Research Institute, Hyogo, Japan with ap-
proval from the Animal Experiment Review Committee in
accordance with the guidelines of the Physiological Society
of Japan. Male Sprague Dawley rats (Japan SLC, Kyoto,
Japan, 7 wks old) received either a vehicle injection of
sodium citrate (0.1 M, pH 4) (control) or streptozotocin
(STZ; 65 mg/kg i.p) to induce type I diabetes. All rats were
on a 12 hr light/dark cycle at 18-25°C and were provided
with food and water ad libitum. Three weeks after vehicle
or STZ injection all rats underwent terminal angiography
experiments. Fasted conscious blood glucose was mea-
sured via the tail vein two days prior to imaging to minim-
ise stress.
Experimental preparation
Under sodium pentobarbital anaesthesia (50 mg/kg i.p.),
rats were intubated, artificially ventilated (Shinano, Tokyo,Japan; 40% oxygen) and the right carotid artery cannulated
with a radiopaque 20-gauge BD Angiocath catheter (Becton
Dickinson, Inc., Sandy, Utah, USA), placing the tip at
the entrance of the aortic valve. Body temperature was
maintained at 37°C, using a rectal thermistor coupled with
a thermostatically controlled heating pad. Anaesthesia level
was maintained via additional intraperitoneal boluses of
pentobarbital (25 mg/kg/h). Sodium lactate (Sigma-Aldrich
Japan K.K., Tokyo, Japan) was administered intravenously
via the right jugular vein to maintain body fluids (3.0 ml/
hr). A 0.3 ml sample of venous blood was collected in
EDTA coated tubes, centrifuged at 4°C for 15 min at
5000 rpm and plasma removed for storage at −20°C until
subsequent triglyceride concentration determination (SRL
Inc., Tachigawa, Tokyo, Japan). A catheter filled with hep-
arinised saline (12 units/ml), was inserted into the right
femoral artery to record arterial pressure via a pressure
transducer (MLT0699, AD Instruments, NSW, Australia)
using CHART software (v5.4.1, AD Instruments, NSW,
Australia) to determine mean arterial pressure (MAP) and
heart rate (HR), simultaneous with recordings of the cam-
era trigger over the cardiac cycle.
Angiography protocol
Each rat was then placed in line with the horizontal X-ray
beam and SATICON detector system (Hitachi Denshi
Techno-system, Ltd., Tokyo, Japan and Hamamatsu Pho-
tonics, Shizuoka, Japan), as described previously [6]. Pan-
curonium bromide (Mioblock; 2 mg/kg, Sankyo, Tokyo,
Japan,) was administered for neuromuscular blockade to
prevent spontaneous breathing when artificial ventilation
was briefly stopped during imaging. Iodinated contrast
medium (Iomeron 350; Bracco-Eisai Co. Ltd, Tokyo, Japan)
was injected intrarterially as a bolus (0.3 – 0.5 ml at
0.4 ml/s) into the aorta with a clinical autoinjector
(Nemoto Kyorindo, Tokyo, Japan) at the start of image
recording scans. At least 10 minutes was allowed for renal
clearance of contrast between imaging scans. During each
cine-scan, monochromatic X-rays at 33.2 keV (energy band-
width 20–30 eV) and a flux ~1010 photons/mm2/s, passed
through the rats chest and were recorded on the SATICON
detector at 30 frames/s at 10-bit resolution for ~3 s
intervals. For each cine-scan, 100 frames were recorded
with a short shutter open time of 1.5-2.0 ms/frame and a
9.5 μm equivalent pixel size for the 9.5 × 9.5 mm input
field with images stored in 1024 × 1024 pixel format.
Experimental protocol
Endothelium-dependent and –independent vasodilatory
responses were recorded in control (n = 6) and diabetic
(n = 8) animals. Angiogram series were recorded at the
end of 5 minute infusions of vehicle (sodium lactate
3.0 ml/hr), ACh (3.0 μg/kg/min), sodium nitroprusside
(SNP 3.0 μg/kg/min), during vehicle infusion 30 minutes
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lin production with Nω-nitro-l-arginine methyl ester (L-
NAME, 10 mg/kg iv. bolus) and sodium meclofenamate
(2 mg/kg iv. bolus) respectively. For simplicity, combined
blockade refers to L-NAME +meclofenamate treatment
together. Endothelium-dependent vasodilation was then
assessed during combined blockade with a repeat infu-
sion of ACh (3.0 μg/kg/min). A final image series was
recorded 10 minutes after administration of fasudil hy-
drochloride (10 mg/kg iv. ROCK inhibitor, HA1077,
Tocris) [22]. Hence, all rats were imaged during 6 con-
secutive treatment periods in total.
Tissue collection histology and immunohistochemistry
Hearts were fixed in 10% neutral buffered formalin and
stored in 70% ethanol. All histological and immunohisto-
chemical sections were imaged using the Aperio ScanScope
XT Slide Scanner (Aperio Technologies, Inc., CA, USA)
system. The proportional area of the stained protein was
automatically quantified using the Positive Pixel Count
v9 algorithm on Aperio Imagescope (v11.0.2.725, Aperio
Technologies). Non-round vessels, resulting from oblique
transection or branching, were excluded from quantifica-
tion of fibrosis and media-to-lumen ratio.
In 4 μm thick sections of LV the vessel media-to-
lumen ratio (the area of the vessel media wall divided by
the area of the total blood vessel lumen) was calculated
[21]. Myocardial interstitial and perivascular fibrosis was
assessed using picrosirius red stained LV sections [6].
Perivascular fibrosis was evaluated around coronary ar-
terioles, as the ratio of the area of fibrosis immediately
surrounding the intramyocardial blood vessel walls to
the total area of the vessel [21].
Capillary density in the myocardium was detected as
the proportion of positively stained endothelial cells with
murine-specific endothelial cell marker isolectin B4 (1:50,
Vector Laboratories, Inc, Burlingame, CA, USA) [23]. Brief-
ly, after dewaxing and heat-mediated antigen retrieval, non-
specific protein binding was blocked with 20% normal goat
serum (Dako, Golstrup, Denmark). Sections were then in-
cubated with biotinylated isolectin B4 at 4°C over-night,
followed by avidin-biotin horseradish peroxidase (Vector
Laboratories, Inc, Burlingame, CA, USA) and diaminoben-
zidine (Vector Laboratories, Inc, Burlingame, CA, USA), as
described previously [23].
ROCK1/2 and nitrotyrosine staining was performed
after subjecting sections to heat-mediated antigen re-
trieval, followed by incubation with 3% H2O2 for 15 min
at room temperature and washing three times with PBS
(pH 7.4) for 5 min each. Nonspecific protein binding was
blocked with 20% normal goat serum (Dako, Golstrup,
Denmark) for 30 min. The sections were then incubated
with the primary antibody overnight at 4°C (ROCK1 1:200
dilution, and ROCK2 1:250 dilution, Abcam, Cambridge,USA; anti-nitrotyrosine 1:400, Millipore 6–284). Following
this, sections were incubated with goat anti-rabbit horse-
radish peroxidase (Dako, Golstrup, Denmark) for 40 or
60 min (ROCK1 and ROCK2/nitrotyrosine respectively) at
room temperature and developed using diaminobenzidine
(Vector Laboratories, Inc, Burlingame, CA, USA) and fi-
nally counter-stained with haematoxylin.Assessment of vessel ID
Vessel ID in individual rats was assessed as previously de-
scribed [6]. Briefly, quantitative analysis of vessel ID was
based on measurements from the middle of discrete vessel
segments in individual cine-radiogram frames using Image-
J (v1.41, NIH, Bethesda, USA) for individual rats during
each treatment period. Angiograms shown in this paper
underwent median filtering (2 pixel radius) to improve ves-
sel clarity for publication purposes only. Arterial vessels
were categorised according to their branching order and
their basal vessel ID size class (40–100 μm, 100–200 μm,
200–300 μm and >300 μm). Reported results for vessel ID
and vessel number in each rat during drug infusions are
expressed as percentage change from baseline (Δ), to ac-
count for differences in absolute baseline vessel ID and
vessel number between groups. Vessel recruitment was
determined as the change in vessel number from base-
line during each treatment for the same field of view.Quantification of segmental vasoconstrictions
Relative change in vessel calibre following vasodilator in-
hibition gives no indication of the number of vessels with
calibres less than the individual’s mean change. Therefore
the number of segmental vasoconstrictions during treat-
ment periods was quantified during the treatment periods
as outlined by Jenkins et al. [6]. Localised segmental vaso-
constrictions were considered to be present when most of
the length of a vessel segment (<100 μm) showed an ID
constriction of >30% of baseline vessel ID.Statistical analysis
Data is expressed as mean ± SEM unless otherwise stated.
The mean vessel ID and the change in ID (%) of each
branching order or vessel size class in individual rats,
in each treatment period, were pooled for group com-
parisons. One-way and two-way ANOVA with Bonferroni
correction for repeated measures was performed to assess
within and between group differences due to treatments.
Following ANOVA, between group comparisons were
made using a 2-tailed Student t-test. The Statistical Pack-
age Software System (SPSS v15, SPSS Inc, Chicago, USA)
was used for all analysis with values of P <0.05 deemed
significant.
Figure 1 Myocardial perivascular fibrosis and media:lumen ratio
in control and diabetic rats. Perivascular collagen ratio (C) was
assessed via picrosirius red staining in control (A) and diabetic (B) rats
(20× objective). Vessel media-to-lumen ratio (F) was assessed via
haematoxylin and eosin staining in control (D) and diabetic (E) rats
(20× objective). There was no significant difference between groups.
Control, n = 6 and diabetic, n = 8. Values expressed as mean ± SEM.
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Animal characteristics
Diabetic animals had higher blood glucose concentra-
tions (P < 0.001), lower final body weight (P < 0.001) and
reduced heart rate under anaesthesia (P < 0.001) versus
controls (Table 1). Kidney to BW ratio was significantly
increased in diabetic animals (P < 0.05) while LV to BW
ratio was comparable to control animals, indicating that
there was no compensatory cardiac hypertrophy. Trigly-
ceride concentration was similar in both groups.
Structural changes and oxidative stress
Myocardial perivascular fibrosis was similar in diabetic
and control rats (Figure 1A-C), as was media-to-lumen
ratio (Figure 1D-F). There was also no significant differ-
ence in myocardial interstitial fibrosis between control
and diabetic animals (Figure 2A-C) or capillary density
(Figure 2D-F). Myocardial ROCK1 expression trended
higher in diabetic versus control animals (Figure 3A-C),
while myocardial ROCK2 expression was borderline sig-
nificantly higher in diabetic animals 3-weeks post STZ
treatment compared to controls (P < 0.053, Figure 3D-F).
Nitrotyrosine levels did not differ significantly between
groups, suggesting that diabetic rats did not experience
consistently higher levels of oxidative stress (Figure 4).
Baseline vessel internal diameter
Representative angiogram frames for all treatment periods
are presented in Figures 5 and 6 for a control and STZ rats
to illustrate the limited individual variability in responses.
Basal vessel ID in diabetic animals was comparable to con-
trol vessel ID across first (214 ±21 vs. 224 ±18 μm), second
(141 ±8 vs. 127 ±6 μm) and third (106 ±6 vs. 93 ±5 μm)
order arterial vessels (Figure 7). Mean total visible vessel
branching segments per animal in the field of view, was
12–18 vessels across all treatments in control animals
and a comparable 11–14 vessels in diabetic rats. The mini-
mum visualised vessel ID recorded across both groups
was 44 μm.Table 1 Body and organ weights, metabolic profile and
haemodynamic variables in anaesthetised control and
diabetic Sprague–Dawley rats
Control Diabetes P
Body Weight (BW, g) 312 ± 10 236 ± 8 <0.001
Blood Glucose (mmol) 5.9 ± 0.4 19.5 ± 1.9 <0.001
MAP (mmHg) 116 ± 6 105 ± 7 NS
Heart Rate (bpm) 436 ± 7 344 ± 11 <0.001
Triglyceride (mmol) 0.57 ± 0.05 0.48 ± 0.21 NS
Heart:BW (%) 0.267 ± 0.005 0.272 ± 0.005 NS
Kidney:BW (%) 0.532 ± 0.019 0.820 ± 0.023 <0.001
Values expressed as mean ± SEM. Control, n = 6 and diabetic, n = 8. MAP:
Mean arterial pressure.
Figure 2 Myocardial interstitial collagen expression and
capillary density in control and diabetic rats. Interstitial collagen
accumulation (C) assessed via picrosirius red staining in control (A)
and diabetic (B) rats (20× objective). Capillary density (F) assessed
via isolectin B4 staining in control (D) and diabetic (E) rats
(40× objective). There was no significant difference between groups.
Control, n = 6 and diabetic, n = 8. Values expressed as mean ± SEM.
Figure 3 Myocardial ROCK1 and ROCK2 immunohistochemistry
in control and diabetic rats. ROCK1 expression (C) in control (A)
and diabetic (B) rats (40× objective). ROCK2 expression (F) in control
(D) and diabetic (E) rats (20× objective). ROCK1 expression was not
significantly different between control and diabetic groups, although
there was a trend towards increased ROCK1 expression in diabetic
rodents. ROCK2 expression was borderline significantly increased
(P < 0.053) in diabetic compared to control animals. Control, n = 6
and diabetic, n = 7. Values expressed as mean ± SEM.
Figure 4 Myocardial nitrotyrosine immunohistochemistry in
control and diabetic rats. Nitrotyrosine expression (C) in control
(A) and diabetic (B) rats (20× objective). Nitrotyrosine expression
was not significantly different between control and diabetic groups.
Control, n = 5 and diabetic, n = 7. Values expressed as mean ± SEM.
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and -independent stimulation
Basal endothelium-dependent vasodilation in diabetics
in response to ACh was on average more pronounced
(>40% of basal ID) than in control rats, but not signifi-
cantly so, based on vessel order or vessel class (Figure 8A
and F). In response to ACh, similar reductions in MAP
(Δ -23.3 ±6.0% vs. -31.4 ±6.5%) and HR (Δ -6.87 ±3.09%
vs. -2.21 ±2.38%, Figure 9) were observed in both groups.
Basal endothelium–independent dilatory responses to SNP
were comparable between diabetic and control animals
(Figure 8B and G). In addition, the MAP and HR response
to SNP was not significantly different between groups
(Figure 9).
Vessel ID response during vasodilator inhibition
Combined blockade of NOS and cyclooxygenase (COX)
caused vasodilation of the coronary vasculature in both
control and diabetic animals. This was evidenced by a
slightly greater vessel ID in both groups compared to
baseline (Figure 8C and H). However, diabetic animals
had a slightly blunted, but not significant, increase in
MAP in response to NOS/COX blockade (Δ 9.7 ±9.7%vs. 31.9 ±16.4%, Figure 9). HR was reduced by similar
amounts in control and diabetic animals following NOS/
COX blockade. Vessel ID response to ACh stimulation
during NOS/COX blockade was not different between
control and diabetic rats (Figure 8D and I). Further, MAP
in control and diabetic animals returned to baseline levels,
Figure 5 Representative synchrotron radiation angiogram of
the coronary vasculature in control and diabetic rats showing
segmental constrictions. Baseline lactate infusion (A & B), ACh
infusion (C & D; 3.0 μg/kg/min), following administration of L-NAME
(10 mg/kg iv. bolus) and meclofenamate (combined, E & F; 2 mg/kg
iv. bolus) and subsequent combined + fasudil treatment (G & H;
10 mg/kg iv). A & B, Baseline response to lactate infusion. C & D,
Control and diabetic, large vessels maintained vessel ID greater than
baseline (black asterisks). E, Control, vessel ID maintained. F, Diabetic
segmental vasoconstriction (white arrow). G, Control, vessel ID
maintained. H, Vasodilation of medium and small arteries (black
arrows) and recruitment of newly visualised small arteries and
arterioles relative to baseline (arrowheads). ‘w’ is a 50 μm tungsten
wire for vessel ID determination.
Figure 6 Additional synchrotron radiation angiograms of the
coronary vasculature in two diabetic rats showing segmental
constrictions. Baseline lactate infusion (A & B), ACh infusion (C & D;
3.0 μg/kg/min), following administration of L-NAME (10 mg/kg iv.
bolus) and meclofenamate (combined, E & F; 2 mg/kg iv. bolus) and
subsequent combined + fasudil treatment (G & H; 10 mg/kg iv).
A & B, Baseline response to vehicle infusion. C & D, Both diabetics
maintained larger vessel ID than baseline (black asterisks).
E & F, Diabetic focal and segmental vasoconstrictions (white arrows).
G & H, Restoration of medium and small arteries to baseline ID,
dilation (black asterisks) and recruitment of newly visualised small
arteries and arterioles relative to baseline (arrowheads). ‘w’ is a
50 μm tungsten wire for vessel ID determination.
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both groups (Figure 9).
Vessel ID response to fasudil treatment
Inhibition of ROCK during NOS/COX blockade resulted
in a significantly greater vessel ID response in second
order vessels in diabetic animals compared to controls
(Δ 36.7 ±8.5% vs. 12.4 ±5.0%, P < 0.05, Figure 8E). This
difference in vessel ID, based on branching order, is also
borne out when vessels were categorised by vessel class,
as fasudil treatment caused a marked increase in vessel
ID in 40-100 μm vessels from diabetic animals compared
to controls (P < 0.05, Figure 8J). There was a trend in both
control and diabetic groups towards a progressively greater
vasodilatory response to fasudil as vessel size class de-
creased. The greater increase in microvessel ID in diabetic
animals did not correspond with a significantly greaterreduction in MAP from baseline in comparison to control
rats (Δ -51.8 ±2.6% vs. -34.5 ±9.5%, P < 0.001, Figure 9).
HR was significantly reduced compared both to baseline
and control animals in response to fasudil in diabetic ani-
mals (P < 0.05, Figure 9).Vessel recruitment during fasudil treatment
The number of vessels visible during ACh or SNP-
mediated vasodilation was not significantly different be-
tween control and diabetic rats. During combined NOS/
COX blockade vessel recruitment was significantly greater
in diabetic animals compared to controls (Δ 19.9 ±10.8%
vs. -12.7 ±7.8%, P < 0.05, Figure 9). Following stimulation
with ACh, in the presence of combined blockade, this dif-
ference in recruitment was reduced. Vessel recruitment in
response to fasudil was markedly increased in diabetic ani-
mals compared to baseline (P < 0.05), however this was
not significantly different to control animals.
Figure 7 Vessel internal diameter categorised by branching
order in control and diabetic animals during baseline vehicle
infusion. There was no significant difference between control and
diabetic animals. Control, n = 6 and diabetic, n = 8. Values expressed
as mean ± SEM.
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One focal constriction (>70% of basal ID) was observed
in a control and a diabetic rat (Figure 5F, white arrow)
during combined blockade, but was abolished by ACh
infusion in the control rat only. Subsequent fasudil treat-
ment was able to completely eliminate the remaining
focal constriction in the diabetic rat. Segmental constric-
tions were more prevalent in diabetic animals, following
combined blockade (Figure 5F and 6E; white arrows and
Figure 10), although this was not significant compared
to control animals. Constrictions occurred predominantly
in the first and second order vessels from diabetic animals
(Figure 10). Consistent with the focal constriction findings,
ACh administration during combined blockade completely
eliminated all segmentally constricted vessels in control but
not diabetic animals (Figure 10). Following fasudil treat-
ment, segmental constrictions were markedly reduced in
diabetic animals (Figures 5H and 6G and H; black arrows)
compared to NOS/COX blockade alone, notably in second
and third order vessels.
Discussion
This study has demonstrated a widespread involvement
of the ROCK signalling pathway in early stage diabetic
coronary dysfunction in vivo. This is supported by data
showing that acute ROCK inhibition alleviates focal and
importantly segmental coronary constrictions in early dia-
betes. Furthermore, acute ROCK inhibition in the diabeticheart results in a significant increase in both micro- and
macrovessel calibre in second and third order branch-
ing segments, following NOS/COX inhibition. This role
for ROCK activation occurs prior to impairment in
endothelium-dependent vasodilation, coronary structure or
the ability of the coronary circulation to recruit micro-
vessels during blood flow increases.
The three-week post diabetes induction time point
used in this experiment, thus allows the investigation of
early functional changes in the diabetic vasculature prior
to changes in coronary structure, which are known to
occur in the later stages of diabetes [24-26]. The extent
of perivascular fibrosis, media-to-lumen ratio and capil-
lary density were similar in diabetic and control animals
and furthermore were consistent with our previous find-
ings [6]. In addition, the likelihood that myogenic, meta-
bolic or endothelial responses differentially affect coronary
tone is limited, as coronary driving pressures were similar
in diabetic and control animals during all treatments.
Vascular function in the presence of nitric oxide
and prostacyclin
Basal coronary endothelial function in diabetic rats was
maintained at 3 weeks post induction, however there are
reports from experiments in isolated coronary arteries
suggesting that by 4 weeks, endothelium-dependent va-
sodilation is impaired [27,28]. Consistent with the current
findings, in our previous study, although there were early
indications basal coronary function was starting to deteri-
orate after 3 weeks of diabetes [6], coronary vasodilation
in vivo was actually maintained. This preserved coronary
endothelium-dependent vasodilation, may be due to a
compensatory increase in coronary COX-2 activity and
expression as demonstrated in early stage diabetic mice
[29]. It may also result from an increased expression of
eNOS, which was found in carotid arteries in early dia-
betes, although this is less likely as the increase in activ-
ity is also associated with greater eNOS uncoupling [30].
Notably, vascular smooth muscle function in diabetic
animals was well maintained as evidenced by similar
endothelium-independent vasodilation when compared to
control animals.
Basal EDHF function and reserve
Vasodilatory responses were similar post-NOS/COX
blockade across all branching orders and vessel classes
in diabetic and control animals although the ability of
the diabetic coronary circulation to recruit new vessels
was slightly enhanced. This increase in visible perfused
segments likely results from an acute compensatory re-
sponse to maintain coronary blood flow following NOS/
COX blockade. Endothelium stimulation following com-
bined blockade facilitates the assessment of the ability of
the remaining endogenous vasodilators namely, EDHF,
Figure 8 Change in vessel ID in control and diabetic animals during infusion of vasoactive compounds, categorised by branching order
and vessel size class. ACh (A & F; 3.0 μg/kg/min), SNP (B & G; 3.0 μg/kg/min), combined (C & H); L-NAME (10 mg/kg iv. bolus) + meclofenamate
(2 mg/kg iv. bolus), combined + ACh (D & I) and combined + fasudil (E & J; 10 mg/kg iv.). Fasudil treatment resulted in a marked increase in
diabetic second order vessel ID and the 40-100 μm small artery-arterioles compared to controls. Control, n = 6 and diabetic, n = 8. Values
expressed as mean ± SEM. †P < 0.05 vs. control.
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Figure 9 Mean arterial pressure (A), heart rate (B) and overall
vessel recruitment (C) in control and diabetic rats. Changes were
assessed during infusion of ACh (3.0 μg/kg/min), SNP (3.0 μg/kg/min),
combined; L-NAME (10 mg/kg iv. bolus) +meclofenamate (2 mg/kg iv.
bolus), combined + ACh and combined + fasudil (10 mg/kg iv.) relative
to baseline (lactate 3.0 ml/hr). A, Diabetic rats had a significant
decrease in blood pressure during combined + fasudil treatment
compared to baseline. B, Heart rate was significantly reduced in
diabetic animals during fasudil treatment compared to baseline and
control rats. C, Diabetic rats had significantly greater vessel recruitment
during combined NOS/COX blockade compared to control animals.
Control, n = 6 and diabetic, n = 8. Values expressed as mean ± SEM.
*P < 0.05, ^P < 0.001 vs. baseline. †P < 0.05 vs. control.
Figure 10 The occurrence of segmental constrictions classified
by branching order in control and diabetic rats. Assessed during
administration of ACh (3.0 μg/kg/min), SNP (3.0 μg/kg/min),
combined; L-NAME (10 mg/kg iv. bolus) + meclofenamate (2 mg/kg
iv. bolus), combined + ACh and combined + fasudil (10 mg/kg iv.).
Segmental constrictions predominately occurred in second order
vessels in control animals. In diabetic animals constrictions were
predominant in second order vessels and to a lesser extent in first
order. ACh administration following combined NOS/COX blockade
alleviated first order constrictions while fasudil treatment further
reduced second order constrictions. Segmental constrictions are
expressed as a proportion of total vessels visible. Control, n = 6 and
diabetic, n = 8. Values expressed as mean ± SEM.
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previous study [6], in suggesting that global coronary EDHF
reserve is unchanged in this model of diabetes, as EDHFpathways remain intact and capable of providing sufficient
reserve to overcome any vasoconstrictor influences.
Vessel diameter response to fasudil
To assess the role of ROCK in the diabetic coronary circu-
lation in vivo, this study utilised the potent and selective
ROCK inhibitor fasudil, due to its minimal off-target ef-
fects on related signalling pathways, including myosin
light chain kinase and protein kinase C (PKC) [31]. Fasudil
is non-selective for the isoforms of ROCK, ROCK1, ex-
pressed ubiquitously, except in brain and muscle tissue
and ROCK2, expressed primarily in cardiac and brain tis-
sue [32]. However, it is unlikely that the limited time of
fasudil treatment in the current study would be sufficient
to result in its significant conversion to the more highly
potent and selective, hydroxyfasudil [18] and as such some
of the inhibitory effect of fasudil may result in part from
off-target inhibition of other kinases. Importantly, in the
context of cardiovascular disease and diabetic coronary
dysfunction, both ROCK1 and ROCK2 are expressed in
vascular endothelial and smooth muscle cells [33-35].
In the diabetic coronary microcirculation ROCK inhib-
ition resulted in significantly greater vasodilation compared
to controls that was most evident in the small arteries and
arterioles emerging from the epicardial main artery seg-
ments. Hence, acute fasudil treatment increases global per-
fusion in the early diabetic heart. Consistent with these
Pearson et al. Cardiovascular Diabetology 2013, 12:111 Page 10 of 13
http://www.cardiab.com/content/12/1/111findings, Didion et al. have shown that ROCK inhibition
significantly increased vessel diameter of cerebral arteries
from type-2 diabetic db/db mice but not in controls [20].
Moreover, fasudil has been shown to reverse vasoconstric-
tion in more advanced diabetes [33,36].
Focal and segmental constrictions in diabetes
In the early diabetic state, prior to widespread vessel im-
pairment in coronary endothelium mediated vasodilatation,
we have characterised and quantified focal and segmental
constrictions in the microvasculature [6]. This study also
revealed a strong trend towards an increased incidence of
segmental constrictions in diabetic animals when there is a
deficit in vasodilator production. This suggests that in later
stage diabetes, when the actions of NO and PGI2 are pro-
gressively impaired [37], the coronary circulation may be-
come more vulnerable to constrictions. Therefore, further
assessment of the role these constrictions play in the regu-
lation of coronary perfusion in diabetes remains vital.
Endothelium-dependent stimulation post-NOS/COX
blockade abolished all segmental constrictions in control
but not diabetic animals. More detailed analysis showed
that the segmental constrictions occurred predominantly
in epicardial first order vessels in diabetic animals. This
is somewhat unexpected as small alterations in vascular
tone, at this macrovessel level are less common, as they
can have significant effects on downstream microvascu-
lar perfusion and are actually predictive of longer term
cardiovascular disease risk in type-2 diabetes [38].
A role for ROCK in focal and segmental constrictions
A novel finding in this study, is the in vivo identification
of ROCK as a likely mediator of localised constrictions
in diabetic hearts. This is supported by the fact that
acute ROCK inhibition greatly reduced the incidence of
segmental constrictions following NOS/COX blockade.
Consistent with this, ROCK has previously been shown
to be upregulated in non-diabetic porcine hearts at the
site of coronary artery spasm [39]. Hypercontraction by
ROCK activation and increased myosin binding subunit
phosphorylation in vascular smooth muscle cells appears
to be a key to much vascular dysfunction. Localised ROCK
activation has been implicated in cerebral artery vaso-
spasm following subarachnoid haemorrhage [40], coronary
artery spasm [10], and following coronary artery bypass
[41] and myocardial ischemia [17]. In our study, non-
constricted vascular regions in diabetic animals responded
to ROCK inhibition similarly to that of responses in con-
trol animals, in agreement with findings in the human cor-
onary circulation where ROCK inhibition had minimal
effect on non-spastic segments [42]. This suggests that
during early-stage diabetes there remain vessel segments
where changes in ROCK signalling are not contributing
appreciably to vasomotor responses.Immunostaining for ROCK1 expression in the myocar-
dium and endothelium was not significantly different be-
tween diabetic and control animals although there was a
notable trend towards an increase. While not significant,
our results are in line with previous work which showed
significant ROCK1 expression upregulation in thoracic
aortas from 3-week diabetic rats [43]. ROCK2 expression
was borderline significantly increased in our diabetic an-
imals, as reported in retinal vessels from rats 2 weeks
after inducing diabetes [15]. Irrespective of ROCK ex-
pression levels in the early diabetic heart a functional
role for ROCK activation was clear.
Diabetes is known to increase RhoA expression, the
upstream regulator of ROCK, as shown in the basilar ar-
tery membrane at 2 weeks [44] and aortic homogenates at
4-weeks post STZ [28] in diabetic rodents. Furthermore,
RhoA expression remains elevated in more advanced dia-
betic stages, as described in aorta from 12–14 week old
[13] and 12–40 week old [33] db/db mice. However, to
date the effect of diabetes on coronary ROCK expression
and activity in more advanced stages remain unclear. Lon-
ger term type-2 diabetes studies using aortic and mesen-
teric arteries suggest that ROCK expression is unchanged
[33,36], although whether this is true in the coronary cir-
culation is uncertain. It remains to be determined if RhoA
upregulation drives ROCK activation and localised coron-
ary constrictions in early diabetes.
Possible mechanisms for ROCK-mediated vasoconstriction
There is strong evidence that hyperglycaemia and or hy-
perlipidaemia evoke reactive oxygen species to stimulate
RhoA/Rho-kinase signalling [45]. Remnant lipoproteins,
acting via the RhoA/Rho-kinase pathway to cause coronary
vasospasm are considered to be a major factor in sudden
death in humans [46]. Nevertheless, our findings suggests
that lipids may have a minimal role in the initiation of
ROCK-mediated vasoconstriction in our diabetic animals,
as plasma triglyceride concentrations were comparable
to control animals, contrasting with later diabetic states
[27,47]. Furthermore, the absence of a significant wide-
spread increase in nitrotyrosine levels in the coronary
vessels and myocardium of diabetic rats in this study sug-
gests that oxidative stress is not yet contributing appre-
ciably to ROCK-mediated vasoconstriction at this time
point. Plasma triglycerides and nitrotyrosine are only single
measures of lipid accumulation and oxidative stress, there-
fore further assessment of lipid profiles and other reactive
oxygen and nitrogen species are certainly warranted.
Hyperglycaemia and diacylglycerol accumulation are well
known for inducing activation of multiple PKC isoforms,
and in particular PKCβ, to cause vascular complications
and potentiated vasoconstrictor responses in diabetic cor-
onary arteries [48]. While PKC mediated potentiation of
ET1 constrictor tone is implicated, diabetic myocardial
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quence of PKC activation of downstream inducible NOS/
RhoA/ROCK [49-51]. Kizub et al. also suggest that both
ROCK and PKC activity evoke enhanced myofilament
Ca2+ sensitivity in muscular arteries in diabetes [52]. It
is important to note however that ROCK inhibition did
not completely alleviate all diabetic segmental constric-
tions, suggesting that although important, ROCK is un-
likely to be the sole mediator of the elevated diabetic
coronary constrictor tone.
Experimental limitations
In comparison to our previous study of early diabetes
[6], the extent of microvascular dysfunction, both focal
and segmental constriction, was slightly less advanced in
this cohort of diabetic animals. This was also the case
with the attenuation of endothelium-dependent vessel
recruitment, which in this study, was not significantly
different from controls. This may be due to a slower devel-
opment in the pathogenesis of diabetes. Indeed, although
the average blood glucose concentration was greater in the
current study, this was also coupled with greater between
animal variability in BG (12.7- 27.9 mmol/L this study vs.
16.7-19.4 mmol/L) [6]. Some diabetic animals in the
current study may have initially had lower blood glucose
concentrations for part of the 3-week period after STZ
induction. This could have led to a shortened period of se-
vere hyperglycaemia and the partial maintenance of coron-
ary microvascular function.
A second limitation of this study that needs to be
recognised is that we cannot accurately determine global
coronary flow or velocity in the anaesthetised rat heart
at this time with the SATICON detector video frame
rates [53]. The advantages of SR microangiography, in-
cluding increased spatial and temporal resolution, far
outweigh this limitation, and allows the assessment of
coronary microvessel diameter, and therefore local distri-
bution of vascular resistance and function in vivo [6,53].
Future directions
Future investigations may focus on treating diabetic car-
diomyopathy with ROCK inhibitors. Indeed recent evi-
dence in diabetic rodents suggests that acute ROCK
inhibition also corrects myocardial contractile function
[49,54]. Fasudil treatment has also been shown to pre-
serve the post-conditioning capacity of the heart during
hyperglycaemia and protect against myocardial infarction
through the opening of mitochondrial ATP-sensitive K
channels [55]. Furthermore, others have shown that inhib-
ition of ROCK reduces monocyte cell adhesion to the
endothelium [56], an early event in plaque formation, and
reduces early plaque formation and the size of established
plaques [57]. Since ROCK is an early contributor to cor-
onary vascular dysfunction, by increasing constrictor toneand subsequently endothelial dysfunction, then chronic
treatment with ROCK inhibitors may help prevent the
diabetic coronary dysfunction completely. A potential ad-
ded benefit of this therapy is likely to be a reduction in
diabetic vascular complications associated with both vas-
cular inflammation and the pro-atherogenic state in dia-
betics [56].Conclusions
In summary, we have confirmed that in vivo imaging using
SR is a powerful means of investigating the intact coron-
ary circulation. Furthermore, we have shown in vivo, that
in early-diabetic rats increased ROCK activity plays a role
in coronary microvasculature function, as acute ROCK
inhibition increased coronary perfusion. Notably, ROCK-
mediated vasoconstriction was not a consequence of in-
creased oxidative stress, inferring that it was most likely
mediated by increased activation of myosin light chain
phosphatase. However, at this early diabetic stage the
ROCK mediated increase in vasoconstrictor tone is nor-
mally offset by NO and PGI2. Nevertheless, these findings
highlight the potential importance of the ROCK signalling
pathway in diabetic coronary vasculature and provide a
promising target for future therapeutic interventions.
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